Clinical Trial Detail

NCT ID NCT01844986
Title Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

ovarian endometrial cancer

peritoneum cancer

fallopian tube cancer

Therapies

Olaparib

Age Groups: adult senior

No variant requirements are available.